



FINANCIAL TEAR SHEET

Corporate Profile

Abeona Therapeutics is focused on developing and delivering gene therapy and plasma-based products for severe and life-threatening rare diseases. Developing therapies for rare disease requires new approaches and strong collaboration between researchers, industry, regulators and patient groups. Abeona was forged from the company's close collaborations with key stakeholders all dedicated to transforming new biotechnology insights into breakthrough treatments for rare diseases such as Sanfilippo disorder, Batten disease, Fanconi anemia and other rare disorders.

Primary IR Contact

Andre'a Lucca
 Director of Communications
 PlasmaTech
 Biopharmaceuticals, Inc.
Phone: 212-786-6208
E-mail:
alucca@plasmatechbio.com

Stock Performance

ABEO (Common Stock)

Exchange	NASDAQ CM (US Dollar)
Price	\$16.75
Change (%)	▲ 0.25 (1.52%)
Volume	1,106,087
52 Week Low	\$4.05
Market Cap	\$664,739,774
Rolling EPS	-0.60
PE Ratio	0
Shares Outstanding	40,287,259



Data as of September 19, 2017 4:00 p.m. ET

Recent Press Releases & Upcoming Events

August 29, 2017

Abeona Therapeutics Receives FDA Breakthrough Therapy Designation for EB-101 Autologous Cell Therapy in Epidermolysis Bullosa

August 17, 2017

Abeona Therapeutics to Host Gene Therapy R&D Day on October 11, 2017

August 15, 2017

Abeona Therapeutics Reports Second Quarter 2017 Financial Results and Recent Business Highlights

Date	Title
September 25, 2017 through September 27, 2017	Cantor Fitzgerald's 3rd Annual Healthcare Conference Location New York City, NY
October 4, 2017 through October 6, 2017	Cell and Gene – Meeting on the Mesa Location La Jolla, CA
October 11, 2017	Abeona Therapeutics R & D Day Location New York, NY

SEC Filings

Filing Date	Form
September 15, 2017	SC 13G
August 14, 2017	10-Q
May 18, 2017	8-K
May 15, 2017	10-Q

Data provided by Nasdaq. Minimum 15 minutes delayed.

Corporate Governance